title: Patient-reported outcomes in chronic gout: a report from OMERACT 10.
abstract: OBJECTIVE
  To summarize the endorsement of measures of patient-reported outcome (PRO) domains in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10).
  
  
  METHODS
  During the OMERACT 10 gout workshop, validation data were presented for key PRO domains including pain [pain by visual analog scale (VAS)], patient global (patient global VAS), activity limitation [Health Assessment Questionnaire-Disability Index (HAQ-DI)], and a disease-specific measure, the Gout Assessment Questionnaire version 2.0 (GAQ v2.0). Data were presented on all 3 aspects of the OMERACT filters of truth, discrimination, and feasibility. One PRO, health-related quality of life measurement with the Medical Outcomes Study Short-form 36 (SF-36), was previously endorsed at OMERACT 9.
  
  
  RESULTS
  One measure for each of the 3 PRO of pain, patient global, and activity limitation was endorsed by > 70% of the OMERACT delegates to have appropriate validation data. Specifically, pain measurement by VAS was endorsed by 85%, patient global assessment by VAS by 73%, and activity limitation by HAQ-DI by 71%. GAQ v2.0 received 30% vote and was not endorsed due to several concerns including low internal consistency and lack of familiarity with the measure. More validation studies are needed for this measure.
  
  
  CONCLUSIONS
  With the endorsement of one measure each for pain, patient global, SF-36, and activity limitation, all 4 PRO for chronic gout have been endorsed. Future validation studies are needed for the disease-specific measure, GAQ v2.0. Validation for PRO for acute gout will be the focus of the next validation exercise for the OMERACT gout group.
authors: Medicine Service, Birmingham Veterans Affairs (VA) Medical Center and Division of Rheumatology, Department of Medicine, University of Alabama, Birmingham, AL 35294, USA. jasvinder.md@gmail.com
authors: Jasvinder A
authors: JA
authors: Singh
authors: Will J
authors: WJ
authors: Taylor
authors: Lee S
authors: LS
authors: Simon
authors: Puja P
authors: PP
authors: Khanna
authors: Lisa K
authors: LK
authors: Stamp
authors: Fiona M
authors: FM
authors: McQueen
authors: Tuhina
authors: T
authors: Neogi
authors: Angelo L
authors: AL
authors: Gaffo
authors: Michael A
authors: MA
authors: Becker
authors: Patricia A
authors: PA
authors: MacDonald
authors: Omar
authors: O
authors: Dabbous
authors: Vibeke
authors: V
authors: Strand
authors: Nicola D
authors: ND
authors: Dalbeth
authors: Daniel
authors: D
authors: Aletaha
authors: N Lawrence
authors: NL
authors: Edwards
authors: H Ralph
authors: HR
authors: Schumacher
mesh_terms: D002908:Chronic Disease; D004185:Disability Evaluation; D005240:Feasibility Studies; D006073:Gout / Q000188:drug therapy*; D006074:Gout Suppressants / Q000627:therapeutic use*; D006801:Humans; D017063:Outcome Assessment, Health Care / Q000379:methods*; D010147:Pain Measurement; D015203:Reproducibility of Results; D057566:Self Report / Q000592:standards*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D006074:Gout Suppressants